Review Article: Impact of Ivabradine on Cardiovascular Morbidity

Abstract

Heart failure is a complex clinical syndrome with a high incidence all over the world. Although various types of pharmacological
and device therapies are available, the control of increased heart rate (HR) is critical. The bradycardic agent, ivabradine (IVA),
has been displayed to reduce HR by inhibiting the funny current (If). The underlying mechanism states that ivabradine can enter the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels and bind to the intracellular side, subsequently inhibiting the If